Randomised controlled trial comparing cisatracurium and vecuronium infusions in a paediatric intensive care unit

Intensive Care Medicine

Volumn 31, Issue 5, 2005, Pages 686-692

  Burmester, Margarita ^a   Mok, Quen ^b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

Cisatracurium; Mechanical ventilation; Neuromuscular blockade; Paediatric intensive care unit; Train of Four; Vecuronium

Indexed keywords

CISATRACURIUM; NEUROMUSCULAR BLOCKING AGENT; VECURONIUM;

ADOLESCENT; ARTICLE; ARTIFICIAL VENTILATION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INFUSION; DRUG SCREENING; FEMALE; HUMAN; INFANT; INTENSIVE CARE UNIT; MALE; NERVE STIMULATION; NEUROMUSCULAR BLOCKING; NEUROMUSCULAR FUNCTION; PEDIATRIC HOSPITAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE;

ATRACURIUM; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; LINEAR MODELS; MALE; NEUROMUSCULAR BLOCKING AGENTS; PROSPECTIVE STUDIES; RESPIRATION, ARTIFICIAL; STATISTICS, NONPARAMETRIC; VECURONIUM BROMIDE;

EID: 18844455306     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00134-005-2615-3     Document Type: Article

References (33)

1. Rudis MI, Guslits BJ, Peterson EL, Hathaway SJ, Angus E, Beis S, Zarowitz BJ (1996) Economic impact of prolonged motor weakness complicating neuromuscular blockade in the intensive care unit. Crit Care Med 24:1749-1756
2. Segredo V, Caldwell JE, Matthay MA, Sharma ML, Gruenke LD, Miller RD (1992) Persistent paralysis in critically ill patients after long-term administration of vecuronium. N Engl J Med 327:524-528
3. Barnes PK, Renzy-Martin N, Thomas VJ, Watkins J (1986) Plasma histamine levels following atracurium. Anaesthesia 41:821-824
4. Chapple DJ, Miller AA, Ward JB, Wheatley PL (1987) Cardiovascular and neurological effects of laudanosine. Studies in mice and rats, and in conscious and anaesthetized dogs. Br J Anaesth 59:218-225
5. Bion JF, Bowden MI, Chow B, Honisberger L, Weatherley BC (1993) Atracurium infusions in patients with fulminant hepatic failure awaiting liver transplantation. Intensive Care Med 19 [Suppl 8]
6. Manthous CA, Chatila W (1995) Atracurium and status epilepticus? Crit Care Med 23:1440-1442
7. Lepage JY, Malinovsky JM, Malinge M, Lechevalier T, Dupuch C, Cozian A, Finaud M, Souron R (1996) Pharmacodynamic dose-response and safety study of cisatracurium (51W89) in adult surgical patients during N2O-O2-opioid anesthesia. Anesth Analg 83:823-829
8. Kisor DF, Schmith VD, Wargin WA, Lien CA, Ornstein E, Cook DR (1996) Importance of the organ-independent elimination of cisatracurium. Anesth Analg 83:1065-1071
9. Soukup J, Doenicke A, Hoernecke R, Qass J (1997) Cisatracurium-is the stereoisomer an "ideal" relaxant? Histamine liberation and tryptase determination after bolus administration of cistracurium: a comparison with vecuronium. Anaesthesist 46:486-491
10. Prielipp RC, Coursin DB, Scuderi PE, Bowton DL, Ford SR, Cardenas VJ Jr, Vender J, Howard D, Casale EJ, Murray MJ (1995) Comparison of the infusion requirements and recovery profiles of vecuronium and cisatracurium 51W89 in intensive care unit patients. Anesth Analg 81:3-12
11. Murray MJ, Cowen J, DeBlock H, Erstad B, Gray AW Jr, Tescher AN, McGee WT, Prielipp RC, Susla G, Jacobi J, Nasraway SA Jr, Lumb PD, Task Force of the American College of Critical Care Medicine (ACCM) of the Society of Critical Care Medicine (SCCM) (2002) Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. Crit Care Med 30:142-156
12. Taivainen T, Meakin GH, Meretoja OA, Wirtavuori K, Perkins RJ, Murphy AK, Fisher GR, Waiter MR (2000) The safety and efficacy of cisatracurium 0.15 mg.kg(-1) during nitrous oxide-opioid anaesthesia in infants and children. Anaesthesia 55:1047-1051
13. Brandom BW, Woelfel SK, Ference A, Dayal B, Cook DR, Kerls S (1998) Effects of cisatracurium in children during halothane-nitrous oxide anesthesia. J Clin Anesth 10:195-199
14. Meretoja OA, Taivainen T, Wirtavuori K (1996) Cisatracurium during halothane and balanced anaesthesia in children. Paediatr Anaesth 6:373-378
15. Ruiter J de, Crawford MW (2001) Dose-response relationship and infusion requirement of cisatracurium besylate in infants and children during nitrous oxide-narcotic anesthesia. Anesthesiology 94:790-792
16. Tobias JD (1997) A prospective evaluation of the continuous infusion of cisatracurium for neuromuscular blockade in the pediatric intensive care unit patient: efficacy and dosage requirements. Am J Ther 4:287-290
17. Odetola FO, Bhatt-Mehta V, Zahraa J, Moler FW, Custer JR (2002) Cisatracurium infusion for neuromuscular blockade in the pediatric intensive care unit: a dose-finding study. Pediatr Crit Care Med 3:250-254
18. Tobias JD (1997) Increased cis-atracurium requirements during prolonged administration to a child. Can J Anaesth 44:82-84
19. Rudis MI, Sikora CA, Angus E, Peterson E, Popovich J Jr, Hyzy R, Zarowitz BJ (1997) A prospective, randomized, controlled evaluation of peripheral nerve stimulation versus standard clinical dosing of neuromuscular blocking agents in critically ill patients. Crit Care Med 25:575-583
20. Newman PJ, Quinn AC, Grounds RM, Hunter JM, Boyd AH, Eastwood NB, Pollard BJ, Pearson AJ, Harper NJ, Beale RJ, Sutjarittam M, Elliot JM, Bion JF (1997) A comparison of cisatracurium (51W89) and atracurium by infusion in critically ill patients. Crit Care Med 25:1139-1142
21. Hodges UM (1996) Vecuronium infusion requirements in paediatric patients in intensive care units: the use of acceleromyography. Br J Anaesth 76:23-28
22. Segredo V, Caldwell JE, Wright PMC, Sharma ML, Gruenke LD, Miller RD (1998) Do the pharmacokinetics of vecuronium change during prolonged administration in critically ill patients? Br J Anaesth 80:715-719
23. Kanji S, Barletta JF, Janisse JJ, Kruse JA, Devlin JW (2002) Tachyphylaxis associated with continuous cisatracurium versus pancuronium therapy. Pharmacotherapy 22:823-830
24. Harper NJ (1993) Neuromuscular blocking drugs: practical aspects of research in the intensive care unit. Intensive Care Med 19 [Suppl 5]
25. Pena O, Prestjohn S, Guzzetta CE (2000) Agreement between muscle movement and peripheral nerve stimulation in critically ill pediatric patients receiving neuromuscular blocking agents. Heart Lung 29:309-318
26. Davis NA, Rodgers JE, Gonzalez ER, Fowler AA, III (1998) Prolonged weakness after cisatracurium infusion: a case report. Crit Care Med 26:1290-1292
27. Toh KW, Deacock SJ, Fawcett WJ (1999) Severe anaphylactic reaction to cisatracurium. Anesth Analg 88:462-464
28. Clendenen SR, Harper JV, Wharen RE Jr, Guarderas JC (1997) Anaphylactic reaction after cisatracurium. Anesthesiology 87:690-692
29. Briassoulis G, Hatzis T, Mammi P, Alikatora A (2000) Persistent anaphylactic reaction after induction with thiopentone and cisatracurium. Paediatr Anaesth 10:429-434
30. Legros CB, Orliaguet GA, Mayer MN, Labbez F, Carli PA (2001) Severe anaphylactic reaction to cisatracurium in a child. Anesth Analg 92:648-649
31. Krombach J, Hunzelmann N, Koster F, Bischoff A, Hoffmann-Menzel H, Buzello W (2001) Anaphylactoid reactions after cisatracurium administration in six patients. Anesth Analg 93:1257-1259
32. Zarowitz BJ, Rudis MI, Lai K, Petitta A, Lulek M (1997) Retrospective pharmacoeconomic evaluation of dosing vecuronium by peripheral nerve stimulation versus standard clinical assessment in critically ill patients. Pharmacotherapy 17:327-332
33. Splinter WM, Isaac LA (2001) The pharmacoeconomics of neuromuscular blocking drugs: a perioperative cost-minimization strategy in children. Anesth Analg 93:339-344